vs
Side-by-side financial comparison of Butterfly Network, Inc. (BFLY) and Intellia Therapeutics, Inc. (NTLA). Click either name above to swap in a different company.
Butterfly Network, Inc. is the larger business by last-quarter revenue ($31.5M vs $23.0M, roughly 1.4× Intellia Therapeutics, Inc.). Butterfly Network, Inc. runs the higher net margin — -48.5% vs -416.2%, a 367.6% gap on every dollar of revenue. On growth, Intellia Therapeutics, Inc. posted the faster year-over-year revenue change (78.8% vs 41.0%). Butterfly Network, Inc. produced more free cash flow last quarter ($7.9M vs $-69.4M). Over the past eight quarters, Butterfly Network, Inc.'s revenue compounded faster (33.6% CAGR vs -10.8%).
Butterfly Network, Inc. is a digital health company that develops, manufactures and sells affordable, portable whole-body ultrasound devices powered by proprietary semiconductor technology. It serves clinical professionals, healthcare facilities, and home care users across global markets, with a core mission to expand access to medical imaging for underserved communities.
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineere...
BFLY vs NTLA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $31.5M | $23.0M |
| Net Profit | $-15.3M | $-95.8M |
| Gross Margin | 67.3% | — |
| Operating Margin | -53.0% | -428.9% |
| Net Margin | -48.5% | -416.2% |
| Revenue YoY | 41.0% | 78.8% |
| Net Profit YoY | 15.5% | 25.7% |
| EPS (diluted) | $-0.06 | $-0.81 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $31.5M | $23.0M | ||
| Q3 25 | $21.5M | $13.8M | ||
| Q2 25 | $23.4M | $14.2M | ||
| Q1 25 | $21.2M | $16.6M | ||
| Q4 24 | $22.4M | $12.9M | ||
| Q3 24 | $20.6M | $9.1M | ||
| Q2 24 | $21.5M | $7.0M | ||
| Q1 24 | $17.7M | $28.9M |
| Q4 25 | $-15.3M | $-95.8M | ||
| Q3 25 | $-34.0M | $-101.3M | ||
| Q2 25 | $-13.8M | $-101.3M | ||
| Q1 25 | $-14.0M | $-114.3M | ||
| Q4 24 | $-18.1M | $-128.9M | ||
| Q3 24 | $-16.9M | $-135.7M | ||
| Q2 24 | $-15.7M | $-147.0M | ||
| Q1 24 | $-21.8M | $-107.4M |
| Q4 25 | 67.3% | — | ||
| Q3 25 | -17.5% | — | ||
| Q2 25 | 63.7% | — | ||
| Q1 25 | 63.0% | — | ||
| Q4 24 | 61.5% | — | ||
| Q3 24 | 59.5% | — | ||
| Q2 24 | 58.6% | — | ||
| Q1 24 | 58.2% | — |
| Q4 25 | -53.0% | -428.9% | ||
| Q3 25 | -163.5% | -808.9% | ||
| Q2 25 | -68.9% | -772.2% | ||
| Q1 25 | -87.0% | -726.6% | ||
| Q4 24 | -77.5% | -1059.9% | ||
| Q3 24 | -83.9% | -1589.0% | ||
| Q2 24 | -80.2% | -1998.6% | ||
| Q1 24 | -128.1% | -394.0% |
| Q4 25 | -48.5% | -416.2% | ||
| Q3 25 | -158.1% | -735.2% | ||
| Q2 25 | -59.2% | -710.8% | ||
| Q1 25 | -65.8% | -687.6% | ||
| Q4 24 | -81.0% | -1001.2% | ||
| Q3 24 | -82.3% | -1489.5% | ||
| Q2 24 | -73.1% | -2112.6% | ||
| Q1 24 | -123.2% | -371.3% |
| Q4 25 | $-0.06 | $-0.81 | ||
| Q3 25 | $-0.13 | $-0.92 | ||
| Q2 25 | $-0.06 | $-0.98 | ||
| Q1 25 | $-0.06 | $-1.10 | ||
| Q4 24 | $-0.09 | $-1.27 | ||
| Q3 24 | $-0.08 | $-1.34 | ||
| Q2 24 | $-0.07 | $-1.52 | ||
| Q1 24 | $-0.10 | $-1.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $150.5M | $449.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $196.0M | $671.4M |
| Total Assets | $296.5M | $842.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $150.5M | $449.9M | ||
| Q3 25 | $144.2M | $511.0M | ||
| Q2 25 | $148.1M | $459.7M | ||
| Q1 25 | $155.2M | $503.7M | ||
| Q4 24 | $88.8M | $601.5M | ||
| Q3 24 | $93.8M | $658.1M | ||
| Q2 24 | $102.1M | $691.1M | ||
| Q1 24 | $112.7M | $791.3M |
| Q4 25 | $196.0M | $671.4M | ||
| Q3 25 | $203.8M | $748.4M | ||
| Q2 25 | $232.8M | $715.3M | ||
| Q1 25 | $239.7M | $779.9M | ||
| Q4 24 | $168.8M | $872.0M | ||
| Q3 24 | $181.8M | $962.6M | ||
| Q2 24 | $194.3M | $971.1M | ||
| Q1 24 | $204.0M | $1.0B |
| Q4 25 | $296.5M | $842.1M | ||
| Q3 25 | $290.0M | $925.3M | ||
| Q2 25 | $313.3M | $898.9M | ||
| Q1 25 | $318.4M | $986.2M | ||
| Q4 24 | $256.1M | $1.2B | ||
| Q3 24 | $265.3M | $1.2B | ||
| Q2 24 | $273.1M | $1.2B | ||
| Q1 24 | $284.3M | $1.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $9.0M | $-69.3M |
| Free Cash FlowOCF − Capex | $7.9M | $-69.4M |
| FCF MarginFCF / Revenue | 25.2% | -301.6% |
| Capex IntensityCapex / Revenue | 3.4% | 0.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-16.0M | $-395.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $9.0M | $-69.3M | ||
| Q3 25 | $-2.9M | $-76.9M | ||
| Q2 25 | $-7.2M | $-99.6M | ||
| Q1 25 | $-11.7M | $-148.9M | ||
| Q4 24 | $-3.1M | $-85.2M | ||
| Q3 24 | $-7.9M | $-84.8M | ||
| Q2 24 | $-10.0M | $-58.2M | ||
| Q1 24 | $-20.7M | $-120.7M |
| Q4 25 | $7.9M | $-69.4M | ||
| Q3 25 | $-3.9M | $-76.9M | ||
| Q2 25 | $-8.1M | $-99.9M | ||
| Q1 25 | $-12.0M | $-149.7M | ||
| Q4 24 | $-3.5M | $-86.2M | ||
| Q3 24 | $-8.3M | $-86.1M | ||
| Q2 24 | $-10.7M | $-59.2M | ||
| Q1 24 | $-21.8M | $-123.2M |
| Q4 25 | 25.2% | -301.6% | ||
| Q3 25 | -18.2% | -558.2% | ||
| Q2 25 | -34.5% | -701.0% | ||
| Q1 25 | -56.7% | -900.1% | ||
| Q4 24 | -15.8% | -669.4% | ||
| Q3 24 | -40.5% | -945.2% | ||
| Q2 24 | -50.0% | -850.9% | ||
| Q1 24 | -123.5% | -425.7% |
| Q4 25 | 3.4% | 0.5% | ||
| Q3 25 | 4.7% | 0.2% | ||
| Q2 25 | 3.8% | 1.7% | ||
| Q1 25 | 1.7% | 4.4% | ||
| Q4 24 | 1.8% | 7.6% | ||
| Q3 24 | 2.0% | 14.0% | ||
| Q2 24 | 3.4% | 14.5% | ||
| Q1 24 | 6.4% | 8.7% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BFLY
| Products | $18.1M | 57% |
| Software And Other Services | $13.4M | 43% |
NTLA
| Avencell Therapeutics Inc | $21.0M | 91% |
| Other | $1.0M | 4% |
| Avencell | $1.0M | 4% |
